Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 11, 2009, Pages 1048-1054

  Ferreira, Anderson J ^a   Shenoy, Vinayak ^b   Yamazato, Yoriko ^a   Sriramula, Srinivas ^c   Francis, Joseph ^c   Yuan, Lihui ^a   Castellano, Ronald K ^d   Ostrov, David A ^a   Oh, Suk Paul ^a   Katovich, Michael J ^b   Raizada, Mohan K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d 241 Williamson Hall   (United States)

Author keywords

Angiotensin converting enzyme 2; Pulmonary heart disease; Renin angiotensin system

Indexed keywords

1 [(2 DIMETHYLAMINO)ETHYLAMINO] 4 (HYDROXYMETHYL) 7 [(4 METHYLPHENYL)SULFONYLOXY] 9H XANTHEN 9 ONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSINOGEN; INTERLEUKIN 10; MESSENGER RNA; MONOCROTALINE; RENIN; UNCLASSIFIED DRUG; XANTHENE DERIVATIVE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG CIRCULATION; LUNG FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION;

ANIMALS; HYPERTENSION, PULMONARY; INFUSIONS, SUBCUTANEOUS; INTERLEUKIN-10; MALE; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; XANTHONES;

EID: 66249133083     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200811-1678OC     Document Type: Article

References (33)

1. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361: 1533-1544. (Pubitemid 36566349)
2. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:1527-1538.
3. Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis 2008;3:55-70.
4. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118:2372-2379.
5. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008;44:14-30.
6. Minamino T, Christou H, Hsieh CM, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, Kourembanas S. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 2001;98:8798-8803. (Pubitemid 32678107)
7. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007;50:112-119. (Pubitemid 47267736)
8. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637. (Pubitemid 38714099)
9. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;295:L178-L185.
10. Riviere G, Michaud A, Breton C, VanCamp G, Laborie C, Enache M, Lesage J, Deloof S, Corvol P, Vieau D. Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to under nutrition-programmed hypertension in the adult rat. Hypertension 2005;46:1169-1174. (Pubitemid 41533021)
11. Wiener RS, Cao YX, Hinds A, Ramirez MI, Williams MC. Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. J Cell Biochem 2007;101:1278-1291. (Pubitemid 47253726)
12. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, Grossman W, De Marco T, Yeghiazarians Y. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1268-1275.
13. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99:675-691. (Pubitemid 44498302)
14. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-116. (Pubitemid 40966195)
15. Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008;172:1174-1183.
16. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin- converting enzyme Homologue ACE2. Circulation 2003;108:1707-1712.
17. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus ADME, Timens W, Turner AJ, Navis G, van Goor H. The emerging role of ACE2 in physiology and disease. JPathol 2007;212:1-11. (Pubitemid 46746284)
18. Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008;51:1312-1317.
19. Wilson DW, Segall HJ, Pan LC, Lamé MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992;22:307-325. (Pubitemid 23014739)
20. Rabinovitch M. Investigational approaches to pulmonary hypertension. Toxicol Pathol 1991;19:458-469.
21. Ferreira AJ, Shenoy V, Yuan L, Katovich M, Reudelhuber T, Raizada MK. Activation prevents monocrotaline-induced pulmonary hypertension. Hypertension 2008;52:e62.
22. Ferreira AJ, Shenoy V, Ostrov D, Katovich M, Raizada MK. ACE2 activation attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens 2008;26:S20.
23. Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 2002;39:969-975.
24. Hayatdavoudi G, Crapo JD, Miller FJ, O'Neil JJ. Factors determining degree of inflation in intratracheally fixed rat lungs. J Appl Physiol 1980;48:389-393. (Pubitemid 10149641)
25. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 2004;287:L1241-L1247. (Pubitemid 39507203)
26. Rasband WS. ImageJ: image processing and analysis in Java [Internet]. Bethesda, MD: National Institutes of Health; 1997-2008 (Accessed 2008 Nov 3). Available from: http://rsb.info.nih.gov/ij/.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-408. (Pubitemid 34164012)
28. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept 2000;91:45-62.
29. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, Mikata A, Natsume M, Mukaida N, Matsushima K, et al. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1998;78:571-581. (Pubitemid 28246981)
30. Ikeda Y, Yonemitsu Y, Kataoka C, Kitamoto S, Yamaoka T, Nishida K, Takeshita A, Egashira K, Sueishi K. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002;283:H2021-H2028. (Pubitemid 35217037)
31. Song Y, Coleman L, Shi J, Beppu H, Sato K, Walsh K, Loscalzo J, Zhang YY. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol 2008;295:H677-H690.
32. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008;29:367-374.
33. Schrier RW, Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol 2008;3:1232-1237.